Axsome said Q4 FY 2025 total net product revenue was USD 196 million (+65%) and FY 2025 total net product revenue was USD 638.5 million (+66%). Q4 product sales, net were USD 194.7 million and total revenues were USD 196 million; FY product sales, net were USD 633.8 million and total revenues were USD 638.5 million. Q4 net loss was USD 28.6 million (USD -0.56 per share) and FY net loss was USD 183.2 million (USD -3.68 per share). Cash and cash equivalents were USD 322.9 million at Dec. 31, 2025. By product, Q4 AUVELITY net product sales were USD 155.1 million (+68%) and FY AUVELITY net product sales were USD 507.1 million (+74%); Q4 SUNOSI net product revenue was USD 36.7 million (+40%) and FY SUNOSI net product revenue was USD 124.8 million (+32%); Q4 SYMBRAVO net product sales were USD 4.1 million and FY SYMBRAVO net product sales were USD 6.6 million. Axsome reported approximately 225,000 Q4 prescriptions for AUVELITY (+42%), about 54,000 for SUNOSI (+11%), and about 13,000 for SYMBRAVO (up 2.47x vs. Q3). AUVELITY payer coverage was approximately 86% of lives, SUNOSI approximately 82%, and SYMBRAVO approximately 52%; Axsome is expanding the AUVELITY sales force to approximately 600 representatives, expected to complete in Q2 2026. In pipeline and corporate updates, the FDA accepted Axsome’s sNDA for AXS-05 in Alzheimer’s disease agitation with Priority Review and a PDUFA target action date of April 30, 2026. The company said it is on track to submit an NDA for AXS-12 in narcolepsy in Q1 2026 and initiated the Phase 3 FORWARD study of AXS-14 in fibromyalgia in January 2026. Axsome also acquired AZD7325 (now AXS-17) for epilepsy and began tech transfer and Phase 2-enabling activities, and said it resolved SUNOSI patent litigation with Alkem, allowing generic entry on or after Sept. 1, 2040 with pediatric exclusivity, or March 1, 2040 without it, subject to FDA approval and customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9658997-en) on February 23, 2026, and is solely responsible for the information contained therein.